Shareholder Suit Alleges $8.7B Medicare Fraud, $237M Insider Sales at UnitedHealth
UNH sits 56% above its 52-week low of $255.965.
Summary
A derivative lawsuit filed by shareholders accuses UnitedHealth's leadership of systemic misconduct from 2021 to 2025, including inflating Medicare Advantage revenue by $8.7 billion in 2021 alone, using algorithms to deny post-acute care with a 99.7% appeal reversal rate, and routing above-market internal payments to bypass federal profit caps. The suit also alleges executives sold $237 million in stock while material information was undisclosed, and that the company misled a federal court during the Change Healthcare acquisition. This follows the Massachusetts Medicaid fraud lawsuit filed in May and adds significant new allegations of insider trading and accounting manipulation. The complaint cites analyst estimates of up to $20 billion in potential Medicare Advantage clawbacks, a material risk to earnings. Watch for the company's response and any DOJ or CMS action on the Medicare Advantage billing practices.
At the time of this announcement, UNH was trading at $399.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $359B. The 52-week trading range was $255.97 to $461.62. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Benzinga.